COSTA MESA, Calif., August 12, 2005 – Valeant Pharmaceuticals
(NYSE:VRX) has announced that Kinerase®, a luxury skin care line,
will be launching their highly anticipated new skin care collection,
Kinerase Pro+Therapy, at Olympus Fashion Week 2005. Kinerase is the
official skin care sponsor of Fashion Week for the third consecutive
year. Kinerase will hold a press conference at Fashion Week on Monday,
September 12th in the main tent, to launch the high end line, sold exclusively
through dermatologists and plastic surgeons nationwide.
Kinerase Pro+Therapy includes Ultra Rich Night Repair (SRP $149.00),
Skin Smoothing Cleanser (SRP $39.00) and Advanced Repair Serum (SRP
$132.00). It has been developed exclusively for physicians to enable
them to offer advanced topical treatment options that work synergistically
with the Kinerase core products. After the press conference, Courteney
Cox will be making a special in store appearance at Sephora in Union
Square, the exclusive US retail outlet carrying Kinerase core products.
The advanced, anti-aging formulations of Kinerase feature Kinetin,
a plant based extract that allows the skin to retain more moisture,
making the skin feel firmer and healthier, improving the skin’s
overall appearance. In a 24-week study of 0.1% kinetin in Lotion base,
90 percent of participants reported an improvement in the texture of
their skin and 87 percent reported an overall improvement in the appearance
of their skin.
In addition to Pro+Therapy, Kinerase has just launched three new products,
Kinerase Hydrating Antioxidant Mist, Kinerase Under Eye Rescue and the
Kinerase Lip Treatment. These products will bring the Kinerase core
product line to 9, including Lotion, Cream, Cream with SPF 15, Intensive
Eye Cream, Gentle Daily Cleanser, and the C6 Peptide Intensive Treatment.
Kinerase is distributed through dermatologists, plastic surgeons, upscale
spas and Sephora. Kinerase can also be purchased online at www.kinerase.com.
About Valeant
Valeant Pharmaceuticals International is a global, publicly traded,
research-based specialty pharmaceutical company that discovers, develops,
manufactures and markets a broad range of pharmaceutical products. More
information about Valeant can be found at www.valeant.com.
FORWARD-LOOKING STATEMENT
This press release contains forward-looking statements within the meaning
of the federal securities laws relating to expectations, plans or prospects
for Valeant Pharmaceuticals. These statements are based upon the current
expectations and beliefs of Valeant Pharmaceuticals' management and
are subject to certain risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include market acceptance
of new products and other market conditions and factors beyond Valeant
Pharmaceuticals' control, the company’s ability to develop successfully
and introduce line extensions, and the risk factors and other cautionary
statements discussed in Valeant Pharmaceuticals' filings with the U.S.
Securities and Exchange Commission.
